Generic Combivir Tablets - Product information and Uses

Combivir a combination of Lamivudine and zidovudine is used as a treatment for HIV infection. It is a fixed dose combination of two antiretroviral drugs, lamivudine (also called 3TC, with the brand name Epivir) and zidovudine (also called AZT, with the brand name Retrovir). The combination of the two medications has a stronger and more sustained effect than using either drug alone, and hence assists in reducing pill burden and in aiding compliance with the antiretroviral drug therapy.
Both lamivudine and zidovudine are reverse transcriptase inhibitors, which block the action of an enzyme, reverse transcriptase, that the virus requires for reproduction. It reduces the viral load in the body and raises CD4 cell count.

Generic Combivir Tablets - Availability And Packaging

Generic Combivir Tablets is packaged as tablets containing Lamivudine 150 mg and Zidovudine 300 mg.

Generic Combivir Tablets - Warnings and Precautions

Hematologic toxicity/bone marrow suppression including neutropenia and anemia have been associated with the use of zidovudine, one of the components of Generic Combivir Tablets. Symptomatic myopathy associated with prolonged use of zidovudine. Lactic acidosis and hepatomegaly with steatosis, including fatal cases, have been reported with the use of nucleoside analogues including zidovudine.Further treatment has to be suspended if clinical or laboratory findings suggestive of lactic acidosis or pronounced hepatotoxicity occur. Acute exacerbations of hepatitis B have been reported in patients who are co-infected with hepatitis B virus (HBV) and human immunodeficiency virus (HIV-1) and have discontinued lamivudine, a component of Generic Combivir. Monitor hepatic function closely in these patients and, if appropriate, initiate anti-hepatitis B treatment. Generic Combivir Tablets should not be administered with other lamivudine- or zidovudine-containing products or emtricitabine-containing products. Hepatic decompensation, some fatal, has occurred in HIV-1/HCV co-infected patients receiving combination antiretroviral therapy and interferon alfa with/without ribavirin. Discontinue Generic Combivir as medically appropriate and consider dose reduction or discontinuation of interferon alfa, ribavirin, or both. Exacerbation of anemia has been reported in HIV-1/HCV co-infected patients receiving ribavirin and zidovudine. Co-administration of ribavirin and zidovudine is not advised. Pancreatitis: Use with caution in pediatric patients with a history of pancreatitis or other significant risk factors for pancreatitis. Discontinue treatment as clinically appropriate. Immune reconstitution syndrome and redistribution/accumulation of body fat have been reported in patients treated with combination antiretroviral therapy.

Generic Combivir Tablets - Drug Interactions

Concomitant use with the following medications should be avoided: stavudine, zalcitabine, doxorubicin. Bone marrow suppressive/cytotoxic agents may increase the hematologic toxicity of zidovudine.

Side Effects of Combivir Tablets

The most commonly reported adverse reactions (incidence greater than or equal to 15%) in adult and pediatric HIV-1 clinical studies of combination lamivudine and zidovudine (Generic Combivir Tablets) were headache, nausea, malaise and fatigue, nasal signs and symptoms, diarrhea, and cough.

Generic Combivir Tablets - Dosage

The dosage of Generic Combivir Tablets for Adults and Adolescents weighing 30 kg or more is 1 tablet twice daily.

Generic Combivir Tablets - Contraindications

Combivir Tablets are contraindicated in patients with previously demonstrated clinically significant hypersensitivity (e.g., anaphylaxis, Stevens-Johnson syndrome) to Lamivudine or zidovudine or to any inactive ingredient present in Combivir.

Additional Information

Additional Info: Prescribing Information